The O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
the O
other O
known O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
. O

We O
have O
analyzed O
the O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
bilateral I
retinoblastoma I
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

Type B
II I
human I
complement I
C2 I
deficiency I
. O

Type B
II I
complement I
protein I
C2 I
deficiency I
is O
characterized O
by O
a O
selective O
block O
in O
C2 O
secretion O
. O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
transfected O
separately O
into O
L O
- O
cells O
. O

Defective O
dimerization O
of O
von O
Willebrand O
factor O
subunits O
due O
to O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type B
IID I
von I
Willebrand I
disease I
. O

The O
same O
heterozygous O
T O
- O
> O
C O
transition O
at O
nt O
8567 O
of O
the O
von O
Willebrand O
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B
IID I
von I
Willebrand I
disease I
, O
with O
no O
other O
apparent O
abnormality O
. O

We O
conclude O
that O
CyS2010 O
is O
essential O
for O
normal O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
bonding O
of O
carboxyl O
- O
terminal O
domains O
and O
that O
a O
heterozygous O
mutation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
defective O
multimer O
formation O
in O
type B
IID I
von I
Willebrand I
disease I
. O
. O

X O
- O
linked O
adrenoleukodystrophy O
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
patients O
. O

X O
- O
Linked O
adrenoleukodystrophy O
( O
ALD O
) O
is O
a O
genetic O
disease O
associated O
with O
demyelination B
of I
the I
central I
nervous I
system I
, O
adrenal O
insufficiency O
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

Tumor O
suppression O
and O
apoptosis O
of O
human O
prostate B
carcinoma I
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B
carcinomas I
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
. O

We O
report O
the O
functional O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B
adenocarcinoma I
cells O
. O

A O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B
adenocarcinoma I
cell O
line O
. O

These O
data O
functionally O
define O
a O
novel O
genetic O
locus O
, O
designated O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
involved O
in O
tumor O
suppression O
of O
human O
prostate B
carcinoma I
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
functionally O
restored O
in O
prostatic B
adenocarcinoma I
. O
. O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast B
carcinoma I
and O
other O
cancers O
. O

This O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B
carcinoma I
. O

Here O
we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
tumour O
types O
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers O
including O
breast B
carcinoma I
. O

However O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B
tumour I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
in O
susceptibility O
to O
pancreatic B
cancer I
. O
. O

Other O
tumor O
types O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic B
, I
pancreas I
, I
skin I
, I
and I
lung I
cancer I
, O
a O
malignant O
melanoma O
, O
an O
oligodendroglioma O
, O
and O
a O
carcinosarcoma O
. O

No O
correlation O
between O
the O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor O
foci O
, O
and O
manifestation O
of O
nonocular B
tumors I
was O
observed O
. O
. O

In O
vitro O
expression O
of O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency B
of I
ASPA I
and O
should O
therefore O
result O
in O
Canavan O
disease O
. O
. O

This O
localization O
makes O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated O
fatal B
lymphoreticular I
disease I
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
Wiskott O
- O
Aldrich O
syndrome O
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM O
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia O
, O
cataract O
and O
male O
- O
infertility O
. O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
features O
with O
DM O
. O

Plasma O
high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
coronary O
heart O
disease O
( O
CHD B
) O
. O

However O
, O
the O
overall O
prevalence O
of O
definite O
CHD B
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
in O
men O
without O
mutations O
. O

The O
relative O
risk O
( O
RR O
) O
of O
CHD B
was O
1 O
. O

43 O
in O
men O
with O
mutations O
( O
P O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
factors O
, O
the O
RR O
was O
1 O
. O

Increased O
CHD B
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
HDL O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
HDL O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
CHD B
prevalence O
. O

Thus O
, O
genetic O
CETP O
deficiency O
appears O
to O
be O
an O
independent O
risk O
factor O
for O
CHD B
, O
primarily O
due O
to O
increased O
CHD B
prevalence O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
dl O
. O

Influence O
of O
PAX6 O
gene O
dosage O
on O
development O
: O
overexpression O
causes O
severe O
eye B
abnormalities I
. O

Aniridia O
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
box O
gene O
PAX6 O
. O

Whereas O
heterozygotes O
suffer O
from O
iris O
hypoplasia O
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain B
abnormalities I
. O

Strikingly O
, O
mice O
carrying O
multiple O
copies O
on O
a O
wild O
- O
type O
background O
show O
specific O
developmental B
abnormalities I
of I
the I
eye I
, O
but O
not O
of O
other O
tissues O
expressing O
the O
gene O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcriptional O
regulators O
can O
cause O
developmental B
defects I
. O
. O

This O
question O
is O
of O
particular O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B
metabolic I
disorder I
galactosemia O
, O
because O
many O
if O
not O
most O
patients O
studied O
to O
date O
are O
compound O
heterozygotes O
rather O
than O
true O
molecular O
homozygotes O
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
HD O
might O
be O
a O
disorder B
of I
inappropriate I
apoptosis I
. O
. O

Expression O
of O
the O
von B
Hippel I
- I
Lindau I
disease I
tumour I
suppressor O
gene O
during O
human O
embryogenesis O
. O

Germline O
VHL O
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal O
cell O
carcinoma O
and O
phaeochromocytoma B
. O

In O
addition O
, O
somatic O
Inactivation O
of O
the O
VHL O
gene O
is O
frequent O
in O
sporadic O
renal O
cell O
carcinoma O
and O
haemangioblastoma B
. O

We O
describe O
the O
proportion O
of O
hereditary O
breast O
cancer O
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary O
breast O
or O
ovarian O
cancer O
risk O
. O

The O
pattern O
of O
hereditary B
cancer I
in O
14 O
( O
61 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
to O
BRCA1 O
by O
a O
combination O
of O
linkage O
and O
mutation O
analyses O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
fish O
- O
eye O
disease O
) O
. O

Three O
sisters O
were O
shown O
to O
suffer O
from O
fish O
- O
eye O
disease O
( O
FED B
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
. O

Sequencing O
of O
the O
LCAT O
gene O
of O
all O
three O
probands O
revealed O
compound O
heterozygosity O
for O
a O
missense O
mutation O
in O
exon O
4 O
which O
is O
reported O
to O
underlie O
the O
FED B
phenotype O
, O
and O
a O
point O
mutation O
located O
in O
intron O
4 O
( O
IVS4 O
T O
- O
22C O
) O
. O

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
null O
allele O
in O
a O
patient O
with O
FED B
. O

The O
level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
showed O
a O
later O
onset O
of O
cerebellar B
ataxia I
. O

Mutation O
of O
the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
. O

To O
define O
the O
possible O
role O
of O
the O
VHL O
gene O
in O
the O
development O
of O
sporadic O
renal O
cell O
carcinomas O
, O
91 O
different O
parenchymal B
tumours I
of I
the I
kidney I
have O
been O
investigated O
for O
mutation O
of O
the O
VHL O
gene O
by O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
techniques O
. O

Chromosome O
3p O
deletion O
was O
detected O
in O
98 O
per O
cent O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
and O
in O
25 O
per O
cent O
of O
chromophobe O
renal O
cell O
carcinomas O
. O

In O
22 O
of O
the O
43 O
non B
- I
papillary I
renal I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
bands O
were O
detected O
by O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

In O
addition O
, O
15 O
papillary B
renal I
cell I
tumours I
and O
ten O
renal O
oncocytomas O
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL O
gene O
. O

The O
results O
indicate O
that O
mutation O
of O
the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinoma I
. O
. O

A O
muscle O
biopsy O
from O
an O
Emery O
- O
Dreifuss O
muscular O
dystrophy O
( O
EMDM B
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
Western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test O
for O
EDMD O
families O
. O

Thus O
, O
we O
screened O
16 O
endometrial B
carcinomas I
with O
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
homolog O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
. O

Although O
we O
found O
no O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
observed O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I
cell O
line O
. O

These O
ocular O
findings O
are O
consistent O
with O
observations O
in O
ND O
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
pathogenic O
events O
in O
this O
severe O
X B
- I
linked I
recessive I
neurological I
disorder I
. O
. O

Pediatric B
alveolar I
rhabdomyosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
PAX3 O
and O
FKHR O
genes O
. O

Here O
, O
we O
report O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
gene O
, O
which O
we O
have O
designated O
LPP O
( O
lipoma B
preferred O
partner O
gene O
) O
. O

Using O
3 O
- O
RACE O
analysis O
of O
HMGIC O
fusion O
transcripts O
in O
lipoma B
cell O
line O
Li O
- O
501 O
/ O
SV40 O
, O
ectopic O
genetic O
sequences O
were O
obtained O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
using O
somatic O
cell O
hybrids O
) O
and O
FISH O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
were O
found O
to O
originate O
from O
chromosome O
segment O
3q27 O
- O
q28 O
. O

Using O
reverse O
transcriptase O
combined O
with O
polymerase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lipoma B
cell O
lines O
and O
primary B
lipomas I
, O
it O
appeared O
that O
LPP O
is O
frequently O
rearranged O
also O
in O
cases O
without O
a O
cytogenetically O
detectable O
involvement O
of O
3q27 O
- O
q28 O
. O

By O
1 O
year O
, O
these O
mice O
have O
no O
behavioral B
abnormalities I
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O

FISH O
studies O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
7 O
; O
11 O
) O
( O
q31 O
. O
2 O
; O
p13 O
) O
. O

A O
2 O
year O
old O
female O
presenting O
with O
bilateral B
sporadic I
aniridia I
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
within O
band O
p13 O
. O

This O
case O
may O
therefore O
be O
another O
example O
of O
aniridia O
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two O
familial O
aniridia O
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome B
abnormalities I
with O
11p13 O
breakpoints O
. O
. O

The O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
CHRNA4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign B
familial I
neonatal I
convulsions I
, O
autosomal O
dominant O
nocturnal O
frontal O
lobe O
epilepsy O
, O
and O
low O
- O
voltage O
EEG O
. O

The O
sequence O
analysis O
provides O
the O
basis O
for O
a O
comprehensive O
mutation O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
phenotypes O
and O
possibly O
in O
other O
types O
of O
idiopathic B
epilepsies I
. O
. O

ATM O
, O
the O
gene O
mutated O
in O
the O
inherited B
human I
disease I
ataxia O
- O
telangiectasia O
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O

The O
cerebella O
of O
ATM O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
to O
4 O
months O
and O
the O
mice O
have O
no O
gross O
behavioral B
abnormalities I
. O

The O
majority O
of O
mutant O
mice O
rapidly O
develop O
thymic B
lymphomas I
and O
die O
before O
4 O
months O
of O
age O
. O

Molecular O
bases O
of O
combined B
subtotal I
deficiencies I
of I
C6 I
and I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
and I
C7 I
deficiencies I
. O

Combined B
subtotal I
deficiency I
of I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
, O
has O
been O
observed O
in O
homozygous O
form O
in O
two O
families O
. O

The O
haplotype O
has O
been O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
either O
to O
C6 B
or I
C7 I
deficiency I
, O
but O
with O
different O
consequences O
. O

Genetic O
bases O
of O
human O
complement B
C7 I
deficiency I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial O
infections O
, O
especially O
meningitis O
caused O
by O
Neisseria B
meningitidis I
. O

We O
report O
in O
this O
work O
the O
molecular O
bases O
of O
C7D B
in O
two O
unrelated O
Japanese O
males O
. O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
for O
C7D B
in O
case O
1 O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B
of I
complement I
components I
. O
. O

Complete B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
deficiency I
in O
humans O
results O
in O
the O
Lesch O
- O
Nyhan O
syndrome O
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT O
- O
deficient O
mice O
has O
produced O
the O
suggestion O
that O
deficiency O
of O
APRT O
in O
combination O
with O
HPRT B
- I
deficiency I
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

Thus O
, O
APRT O
- O
HPRT O
- O
deficient O
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral B
abnormalities I
associated O
with O
the O
Lesch O
- O
Nyhan O
syndrome O
as O
previously O
suggested O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
cancers I
in O
vivo O
. O

BACKGROUND O
& O
AIMS O
The O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
. O

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
gene O
from O
examination O
of O
pancreatic B
cancers I
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B
cancers I
. O

CONCLUSIONS O
The O
DPC4 O
gene O
may O
play O
a O
role O
as O
a O
tumor O
- O
suppressor O
gene O
in O
a O
fraction O
of O
colorectal B
cancers I
; O
however O
, O
while O
allelic O
loss O
at O
18q21 O
is O
very O
often O
seen O
in O
colorectal B
cancers I
, O
only O
a O
minority O
show O
DPC4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
in O
this O
chromosome O
region O
. O
. O

BACKGROUND O
Allelic O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
. O

METHODS O
The O
expression O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
samples O
from O
patients O
with O
curatively O
resected O
stage B
II I
and I
III I
colorectal I
carcinomas I
. O

RESULTS O
The O
expression O
of O
DCC O
was O
a O
strong O
positive O
predictive O
factor O
for O
survival O
in O
both O
stage B
II I
and I
stage I
III I
colorectal I
carcinomas I
. O

3 O
percent O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
rate O
was O
61 O
. O

In O
patients O
with O
stage B
III I
disease I
, O
the O
respective O
survival O
rates O
were O
59 O
. O

CONCLUSIONS O
DCC O
is O
a O
prognostic O
marker O
in O
patients O
with O
stage B
II I
or I
stage I
III I
colorectal I
cancer I
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage O
III O
cancers O
. O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
type I
2 I
and O
diastrophic O
dysplasia O
. O

Mutations O
in O
the O
diastrophic O
dysplasia O
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias O
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic O
dysplasia O
( O
DTD O
) O
, O
atelosteogenesis B
type I
2 I
( O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST O
chondrodysplasias O
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO B
- I
2 I
, O
one O
with O
DTD O
, O
and O
one O
with O
an O
intermediate O
phenotype O
( O
AO2 B
/ O
DTD O
) O
. O

In O
two O
patients O
( O
DTD O
and O
AO2 B
/ O
DTD O
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
and O
single O
- O
strand O
conformation O
polymorphism O
analysis O
of O
fibroblast O
cDNA O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
- O
type O
DTDST O
allele O
these O
two O
patients O
may O
be O
compound O
heterozygotes O
for O
the O
" O
Finnish O
" O
mutation O
( O
as O
yet O
uncharacterized O
at O
the O
DNA O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
DTDST O
. O

The O
third O
patient O
( O
with O
AO2 B
) O
had O
the O
R279W O
mutation O
compounded O
with O
a O
novel O
mutation O
, O
the O
deletion O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
predicting O
a O
frameshift O
with O
premature O
termination O
. O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 B
or O
DTD O
emphasizes O
the O
overlap O
between O
these O
conditions O
. O

This O
mutation O
has O
not O
been O
found O
so O
far O
in O
8 O
analyzed O
ACG1B B
patients O
, O
suggesting O
that O
it O
allows O
some O
residual O
activity O
of O
the O
sulfate O
transporter O
. O
. O

The O
Wiskott O
- O
Aldrich O
syndrome O
( O
WAS O
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS O
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
extensive O
clinical O
heterogeneity O
. O

Familial O
adenomatous O
polyposis O
( O
FAP O
) O
is O
an O
inherited O
predisposition O
to O
colorectal O
cancer O
characterized O
by O
the O
development O
of O
numerous O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O
region O
. O

Autosomal O
dominant O
primary O
hyperparathyroidism O
and O
jaw O
tumor O
syndrome O
associated O
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
. O

Hereditary O
hyperparathyroidism O
- O
jaw O
tumor O
syndrome O
( O
HPT O
- O
JT O
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Here O
we O
report O
two O
families O
with O
HPT O
- O
JT O
syndrome O
in O
which O
adult O
renal O
hamartomas O
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT O
- O
JT O
syndrome O
. O

Loss O
of O
heterozygosity O
was O
studied O
in O
seven O
renal B
hamartomas I
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw O
tumor O
and O
a O
parathyroid B
tumor I
from O
the O
second O
family O
. O

All O
renal B
hamartomas I
showed O
loss O
of O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
region O
. O

We O
report O
a O
novel O
missense O
change O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
T O
( O
R841W O
) O
, O
found O
in O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
breast B
and I
79 I
ovarian I
cancer I
cases O
from O
Orange O
County O
, O
CA O
. O

In O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast B
, I
ovarian I
, I
or I
other I
cancers I
possibly O
related O
to O
a O
BRCA1 O
defect O
and O
family O
members O
showed O
a O
high O
concordance O
of O
cancer O
incidence O
with O
the O
presence O
of O
R841W O
. O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal O
recessive O
disorder O
ataxia O
- O
telangiectasia O
( O
A O
- O
T O
) O
, O
characterized O
by O
cerebellar O
degeneration O
, O
immunodeficiency O
and O
cancer B
predisposition I
. O

A O
- O
T O
carriers O
were O
reported O
to O
be O
moderately O
cancer B
- I
prone I
. O

Molecular O
basis O
for O
Duarte B
and I
Los I
Angeles I
variant I
galactosemia I
. O

Human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variant I
of I
galactosemia I
( O
D O
/ O
D O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focusing O
and O
50 O
% O
reduction O
in O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
enzyme O
activity O
. O

We O
conclude O
that O
the O
codon O
change O
N314D O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
T O
produces O
the O
LA B
variant I
of I
galactosemia I
and O
that O
this O
nucleotide O
change O
increases O
GALT O
activity O
by O
increasing O
GALT O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O
thermal O
lability O
. O

Recent O
work O
has O
identified O
a O
mouse O
gene O
( O
tsg101 O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
and O
the O
ability O
to O
produce O
metastatic B
tumors I
in O
nude O
mice O
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
of O
these O
cancers O
. O

The O
children O
share O
common O
clinical O
features O
including O
splenomegaly O
and O
lymphadenopathy O
, O
but O
only O
one O
developed O
severe O
autoimmune B
manifestations I
. O

The O
nonsense O
mutation O
, O
which O
is O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
normal O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
persistence O
has O
been O
associated O
with O
mild O
forms O
of O
PLP B
- I
associated I
disease I
in O
both O
humans O
and O
mice O
. O
. O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B
handicapped I
with O
short O
stature O
, O
restricted B
joint I
mobility I
, O
and O
blindness O
but O
is O
mentally O
alert O
and O
leads O
an O
active O
life O
. O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B
, I
breast I
, I
and I
prostate I
cancer I
. O

In O
preliminary O
screens O
, O
mutations O
of O
PTEN O
were O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma B
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate O
cancer O
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast O
cancer O
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B
glioblastomas I
. O

These O
homologies O
suggest O
that O
PTEN O
may O
suppress O
tumor O
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may O
regulate O
tumor O
cell O
invasion O
and O
metastasis B
through O
interactions O
at O
focal O
adhesions O
. O
. O

The O
Schwartz O
- O
Jampel O
syndrome O
( O
SJS O
; O
chondrodystrophic O
myotonia O
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia O
, O
short O
stature O
, O
and O
bone O
dysplasia O
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys O
- O
Drash O
syndrome O
( O
renal B
nephropathy I
, O
gonadal O
anomaly O
, O
predisposition B
to I
WT I
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

WT1 O
mutations O
have O
also O
been O
reported O
in O
juvenile O
granulosa O
cell O
tumour O
, O
non B
- I
asbestos I
related I
mesothelioma I
, O
desmoplastic B
small I
round I
cell I
tumour I
and O
, O
most O
recently O
, O
acute O
myeloid O
leukemia O
. O
. O

A O
mutation O
in O
autosomal B
dominant I
myotonia I
congenita I
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
. O

Autosomal B
dominant I
myotonia I
congenita I
is O
an O
inherited B
disorder I
of I
skeletal I
muscle I
caused O
by O
mutations O
in O
a O
voltage O
- O
gated O
Cl O
- O
channel O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

In O
the O
Japanese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
IDDM2 O
to O
the O
pathogenesis O
of O
IDDM B
. O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
a O
large O
number O
of O
Japanese O
subjects O
with O
multiple O
polymorphisms O
in O
INS O
region O
. O

We O
found O
a O
significant O
association O
of O
the O
INS O
region O
with O
IDDM B
. O

Alleles O
positively O
associated O
with O
IDDM B
in O
INS O
region O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
IDDM B
in O
Caucasian O
population O
, O
although O
positively O
- O
associated O
alleles O
are O
very O
common O
( O
allele O
frequencies O
> O
0 O
. O
9 O
) O
in O
the O
Japanese O
general O
population O
. O

These O
data O
suggest O
that O
IDDM2 O
is O
involved O
in O
the O
genetic O
susceptibility O
to O
IDDM B
in O
Japanese O
. O

The O
high O
frequencies O
of O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
that O
IDDM2 O
locus O
is O
not O
responsible O
for O
the O
low O
incidence O
of O
IDDM B
in O
Japanese O
. O

Deficiency B
of I
terminal I
complement I
components I
is O
generally O
associated O
with O
recurrent O
neisseria B
infections I
. O

We O
studied O
a O
previously O
described O
Swiss O
family O
with O
inherited B
C9 I
deficiency I
. O

Mutations O
in O
the O
arginine O
- O
rich O
protein O
gene O
( O
ARP O
) O
in O
pancreatic B
cancer I
. O

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid O
tumors O
, O
although O
not O
in O
pancreatic B
cancer I
. O

We O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
deletion O
of O
codon O
50 O
of O
the O
ARP O
gene O
in O
different O
tumor B
types I
( O
Shridhar O
et O
al O
. O
, O
1996 O
, O
1996a O
) O
. O

In O
the O
present O
study O
, O
we O
have O
observed O
mutations O
involving O
codon O
50 O
in O
11 O
of O
37 O
pancreatic B
tumors I
. O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic B
tumors I
as O
in O
the O
other O
types O
of O
tumors O
previously O
examined O
. O

In O
addition O
, O
we O
have O
detected O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
tumors I
. O

Mutations O
in O
the O
ARP O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic B
cancer I
, O
as O
well O
as O
many O
other O
cancers O
. O

Difficulties O
in O
the O
ascertainment O
of O
C9 O
deficiency O
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 B
- I
deficient I
subject O
. O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
directing O
hyposynthesis O
of O
a O
defective O
C9 O
. O

In O
the O
present O
study O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast O
and O
/ O
or O
ovarian O
cancer O
and O
tumour O
DNA O
from O
96 O
breast B
carcinomas I
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
gene O
( O
ESR O
) O
. O

Somatic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
tumours O
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
somatic O
ESR O
base O
mutations O
as O
an O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen B
receptor I
- I
positive I
breast I
carcinomas I
. O
. O

Molecular O
heterogeneity O
of O
classical B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O
. O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical O
galactosemia O
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
. O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
proteins O
with O
tumorigenic O
potential O
. O

In O
the O
pediatric O
solid B
tumor I
alveolar O
rhabdomyosarcoma O
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
generates O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
fusion O
proteins O
, O
respectively O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia O
- O
telangiectasia O
and O
Li O
- O
Fraumeni O
syndrome O
, O
respectively O
. O

Atm O
- O
null O
mice O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop O
mainly O
T B
- I
cell I
lymphomas I
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
. O

Myotonic O
dystrophy O
, O
or O
dystrophia B
myotonica I
( O
DM O
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
on O
chromosome O
19q13 O
. O

Although O
the O
DM O
mutation O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B
disease I
remain O
elusive O
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
repress O
vascular O
endothelial O
growth O
factor O
promoter O
activity O
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
renal I
cell I
carcinoma I
( O
RCC O
) O
, O
as O
VHL O
mutations O
have O
been O
found O
in O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
associated I
and I
sporadic I
RCCs I
. O

Recent O
studies O
suggest O
that O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
RCC B
- I
and I
von I
Hippel I
- I
Lindau I
disease I
- I
associated I
tumors I
. O

